Selected Publications 2004 – 2008 (selected from a total of 145 peer-reviewed original publications)

S. K. Kulp, Y.-T. Yang, C.-C. Hung, K.-F. Chen, P.-H. Tseng, Y.-T. Yang, X. Zhu, J.-W. Huang, J. Fowble, and C.-S. Chen (2004) “PDK-1/Akt Signaling Represents a Major COX-2-Independent Target for the Antiproliferative Effect of the Cyclooxygenase-2 Inhibitor Celecoxib in Prostate Cancer Cells” Cancer Res., 64, 1444-1451

Q. Lu, Y.-T. Yang, C.-S. Chen, M. Davis, J. C. Byrd, M. R. Etherton, A. Umar, and C.-S. Chen (2004) “Zn2+-Chelating Motif-Tethered Short-Chain Fatty Acids as a Novel Class of Histone Deacetylase Inhibitors” J. Med. Chem., 47, 467-474

J. Zhu, J.-W. Huang, J. Fowble, P.-H. Tseng, C.-W. Shiau, Y-J. Shaw, S. K. Kulp, and C.-S. Chen (2004) “From the cyclooxygenase-2 inhibitor celecoxib to a novel class of potent Akt-targeted antitumor agents” Cancer Res. 64, 4309-4318

P.-H. Tseng, H.-P. Lin, W. M. Shieh, H. Hu, C. Wang, X. Zhu, and C.-S. Chen (2004) “Selective Activation of TRPC Channels by Phosphophatidylinositol 3,4,5-Trisphosphate” Biochemistry, 43, 11701-11708

Y.-J. Shaw, Y.-T. Yang, J. B. Garrison, N. Kyprianou, and C.-S. Chen (2004) “Pharmacological exploitation of the a1-adrenoreceptor antagonist doxazosin to develop a novel class of antitumor agents that block intracellular Akt activation” J. Med. Chem., 47, 4453-62

H.-P. Lin, S. K. Kulp, P.-H. Tseng, Y.-T. Yang, C.-S. Chen, C.-C. Yang, and C.-S. Chen (2004) “Growth-inhibitory effects of celecoxib in human umbilical vein endothelial cells are mediated through G1 arrest via multiple signaling mechanisms” Mol. Cancer Ther., 3. 1671-80

S. Roychowdhury, R.A., Baiocchi, S. Vourgant, D. Bhatt, B.W. Blaser, A.G. Freud, J. Chou, C.-S. Chen, J.J. Xiao, M. Parthun, K.K. Chan, C.F. Eisenbeis, A.K. Ferketich, M.R. Grever, C.-S. Chen, M.A. Caligiuri (2004) “Selective efficacy of depsipeptide in a xenograft model of Epstein-Barr virus-positive lymphoproliferative disorder” J. Natl. Cancer Inst. 96, 1447-1457

H. Ding, C. Han, J. Zhu, C.-S. Chen, and S. M. D’Ambrosio (2005) “Celecoxib derivatives induce apoptosis via the disruption of mitochondrial membrane potential and activation of caspase 9” Int. J. Cancer, 113, 803-810

C.-W. Shiau, C.-C. Yang, K.-F. Chen, J.-W. Huang, and C.-S. Chen (2005) “Thiazolidenediones mediates apoptosis in prostate cancer cells, in part, via the inhibition of Bcl-xL/Bcl-2 functions independently of PPARg” Cancer Res., 65, 1561-1569

P.-H. Tseng, H.-P. Lin, K.-F. Chen, J. Zhu, J.C C. Byrd, M. R. Grever, B. J. Druker, and C.-S. Chen (2005) “synergistic interactions between imatinib and the novel phosphoinositide-dependent kinase-1 inhibitor OSU-03012 in overcoming imatinib resistance” Blood, 105, 4021-4027

A. J. Johnson, L. L. Smith, J. Zhu, N. A., Heerema, S. Jefferson, M. R. Grever, C.-S. Chen, J. C. Byrd (2005) “A novel celecoxib derivative induces apoptosis in primary CLL cells and transformed B-cll lymphoma via a caspase- and Bcl-2-independent mechanism” Blood, 105, 2504-2509

J.-W. Huang, C.-W. Shiau, Y.-T. Yang, K.-F. Chen, S. K. Kulp, R. W. Brueggemeier, C. L. Shapiro, and C.-S. Chen (2005) “Peroxisome Proliferator-Activated Receptor g-Independent Ablation of Cyclin D1 by Thiazolidenediones and Their Derivatives in Breast Cancer Cells” Mol Pharmacol, 67, 1342-1348

O.S. Gardner, C.-W. Shiau, C.-S. Chen, and L.M. Graves (2005) “PPARg-independent activation of p38 MAPK by thiazolidebediones involves calcium/calmodulin-dependent protein kinase II and protein kinase R: correlation with endoplasmic reticulum stress” J. Biol. Chem., 280, 10109-10118

C,-S, Chen, S.-C. Weng, P.-H. Tseng, H.-P. Lin, and C.-S. Chen (2005) “Nonepigenetic effects of histone deacetylase inhibitors on Akt through reshuffling protein phosphatae-1 complexes” J. Biol. Chem, 280, 38879-38887

Q. Lu, D.-S. Wang, C.-S. Chen, Y.D. Hu, and C.-S. Chen (2005) “Structure-based optimization of phenylbutyrate-derived histone deacetylase inhibitors” J. Med. Chem. 48, 5530-5535

C.-C. Yang, C.-Y. Ku, S. Wei, C.-W. Shiau, C.-S. Chen, J. Pinzone, M.D. Ringel, and C.-S. Chen  (2006) “Peroxisome Proliferator-Activated Receptor g-Independent Repression of Prostate-Specific Antigen Expression by Thiazolidinediones in Prostate Cancer Cells”, Mol Pharmacol, 69, 1564-1570

H.-Y. Lin, C.-S. Chen, S.-P. Lin, J.-R. Weng, and C.-S. Chen (2006) ²Targeting Histone Deacetylase in Cancer Therapy² Med. Res. Rev., 26, 397-413

J.-R. Weng, C.-Y. Chen, J. Pinzone, M.D. Ringel, and C.-S. Chen (2006) ²Beyond PPAR-gamma Signaling. The Multi-Facets of the Antitumor Effect of Thiazolidinediones² Endocrine-Related Cancer, 13, 401-413

C.-W. Shiau, J.-W. Huang, D.-S. Wang, J.-R. Weng, C.-C. Yang C. Li, and C.-S. Chen (2006) “a-Tocopheryl Succinate Induces Apoptosis in Prostate Cancer Cells in part through Inhibition of Bcl-xL/Bcl-2 Function”, J. Biol. Chem,, 281, 11819-11825

R. E. Teresi, C.-W. Shiau, C.-S. Chen, V. K. Chatterjee, K. A. Waite, and C. Eng (2006) “Increased PTEN expression due to transcriptional activation of PPARg by Lovastatin and Rosiglitazone” Int. J. Cancer, 118, 2390-2398

J. W. Huang, C.-W. Shiau, J. Yang, D.-S. Wang, C.-Y. Chen, and C.-S. Chen (2006) Development of Small-Molecule Cyclin D1-Ablative Agents” J. Med. Chem., 49, 4684-4689

S. K. Kulp, C.-S. Chen, D.-S. Wang, C.-Y. Chen, and C.-S. Chen (2006) “Antitumor effects of a novel phenyl-butyrate-based histone deacetylase inhibitor, (S)-HDAC-42, in prostate cancer” Clin. Cancer Res., 12, 5199-5206

P.-H. Tseng, S.-C. Weng, J.-R. Weng, R. W. Brueggemeier, C. L. Shapiro, S. E. Dunn, M. Pollak, and C.-S. Chen (2006) “Overcoming trastuzumab resistance in HER2-overexpressing breast cancer cells by using a novel celecoxib-derived phosphoinositide-dependent kinase-1 inhibitor” Mol. Pharmacol., 70, 1534-1541

C.-C. Yang, Y.-C. Wang, S. Wei, L.-F. Lin, C.-S. Chen, C.-C. Lee, C.-C. Lin, and C.-S. Chen (2007) “Peroxisome Proliferator-Activated Receptor g-Independent Suppression of Androgen Receptor Expression by Troglitazone.  Mechanism and Pharmacological Exploitation” Cancer Res, 67, 3229-3238

C.-S. Chen, Y.-C. Wang, H.-C. Yang, P.-H. Huang, S.K. Kulp, C.-C. Yang, Y.-S. Lu, S. Matsuyama, C.-Y. Chen, and C.-S. Chen (2007) “Histone Deacetylase Inhibitors Sensitize Prostate Cancer Cells to Agents That Produce DNA Double-Strand Breaks by Targeting Ku70 Acetylation” Cancer Res, 67, 5318-5327

Y.-S. Lu, Y. Kashida, S.K. Kulp, J.-H. Hung, D. Wang, Z.-Z. Lin, T.-J. Chen, A.-L. Cheng, and C.-S. Chen (2007) “Efficacy of OSU-HDAC42, a novel phenylbutyrate-based histone deacetylase inhibitor, in murine models of hepatocellular carcinoma” Hepatology, 46, 1119-1130

A. M. Sargeant, R.D. Klein, R.C. Rengel, S.K. Clinton, S.K. Kulp, Y. Kashida, M. Yamaguchi, and C.-S. Chen (2007) “Chemopreventive and bioenergetic signaling effects of PDK1/Akt pathway inhibition in a transgenic mouse model of prostate cancer” Toxicol Pathol, 35, 549-561

J.-R. Weng, C.-H. Tsai, S. K. Kulp. D. Wang, C.-H. Lin, H.-C. Yang, Y. Ma, A. Sargeant, C.-F. Chiu, M.-H. Tsai, and C.-S. Chen (2007) “A potent indole-3-carbinol-derived antitumor agent with pleotropic effects on multiple signaling pathways in prostate cancer cells” Cancer Res, 67, 67, 7815-7824

S. Wei, L.-F. Lin, C.-C. Yang, C.-H. Tsai, Y.-C. Wang, G.-D. Chang, H. Chen, and C.-S. Chen (2007) “Thiazolidineiones modulate the expression of b-catenin and other cell-cycle regulatory proteins by targeting the F-box proteins of SCF E3 ubiquitin ligase independently of PPARg” Mol. Pharmacol., 72, 725-733

Y.-C. Wang, S. K. Kulp, D. Wang, C.-C Yang, A. M. Sargeant, Y. Kashida, M. Yamaguchi, G.-D. Chang, and C.-S. Chen (2008) “Targeting ER-stress and Akt signaling with OSU-03012 and gefitinib or erlotinib to overcome epidermal growth factor receptor inhibitor-resistance in non-small cell lung cancer cells with activated Akt” Cancer Res., in press

J.-H. Hung, Y.-S. Lu, Y.-C. Wang, Y.-H. Ma, D. Wang, S. K. Kulp, N. Muthusamy, J. C. Byrd, A.-L. Cheng, and C.-S. Chen (2008) “FTY720 induces apoptosis in hepatocellular carcinoma cells in part through activation of reactive oxygen species-protein kinase C-delta signaling” Cancer Res, 68, 1204 1213.

J. Yang, S. Wei, D.-S. Wang, Y.-C. Wang, S. K. Kulp, and C.-S. Chen (2008) “Pharmacological exploitation of the peroxisome proliferator-activated receptor g agonist ciglitazone to develop a novel class of androgen receptor-ablative agents” J. Med. Chem, in press

J.-R. Weng, C.-H. Tsai, S. K. Kulp, and C.-S. Chen (2008) “Indole-3-carbinol as a chemopreventive and anti-cancer agent” Cancer Lett, in press (invited review)

S.-C. Weng, Y. Kashida, S. K. Kulp. D. Wang, R. W. Brueggemeier, C. L. Shapiro, and C.-S. Chen (2008) “Sensitizing estrogen receptor-negative cancer cells to tamoxifen with OSU-03012, a novel celecoxib-derived PDK-1/Akt signaling inhibitor” Mol Cancer Ther, in press

S. Wei, H.-C. Yang, H.-C. Chuan, J. Yang, S. K. Kulp, P.-J. Lu, M.-D. Lai, and C.-S. Chen (2008) “Identification of an IkB kinase a-Dependent, SCFb-TrCP-Mediated Pathway for Cyclin D1 Degradation” submitted for publication

A. M. Sargeant, R. C. Ringel, S. K. Kulp, R. D. Klein, S. K. Clinton, Y.-C. Wang, and C.-S. Chen (2008) “Dietary Intake of OSU-HDAC42, a histone deacetylase inhibitor, blocks prostate tumor progression in the TRAMP model” Cancer Res, in revision

[ back to top ]